HSCSHIGH SIGNALFINANCIAL10-K

HSCS exhibits severe financial deterioration with stockholders' equity collapsing 97% to just $205K while burning through 81% of its cash reserves.

The company is approaching financial distress with stockholders' equity nearly wiped out and cash declining from $5.8M to $1.1M, indicating potential going concern issues. The dramatic increase in current liabilities (+111%) combined with plummeting revenue (-77%) suggests the company may struggle to meet near-term obligations and continue operations without additional financing.

Comparing 2025-07-24 vs 2024-07-29View on EDGAR →
FINANCIAL ANALYSIS

HSCS experienced catastrophic financial deterioration across all major metrics, with stockholders' equity virtually eliminated (down 97% to $205K) and cash reserves depleted by 81% to $1.1M. Total assets shrunk 56% while liabilities increased 84%, creating a dangerous liquidity squeeze, and revenue collapsed 77% from an already minimal $19K base. The financial profile suggests a company in severe distress that may require immediate capital infusion or face potential bankruptcy, despite some positive regulatory developments with their FDA breakthrough device designation.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+111.4%
$1.8M→$3.7M

Current liabilities surged 111.4% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
-97.2%
$7.3M→$205K

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-95.1%
$64K→$3K

Capex reduced 95.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
+87.4%
$2K→$4K

Receivables surged 87.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Liabilities
Balance Sheet
+83.8%
$2.2M→$4.0M

Liabilities grew 83.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
-81.1%
$5.8M→$1.1M

Cash declined 81.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Gross Profit
P&L
-80.3%
$13K→$2K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Revenue
P&L
-76.6%
$19K→$4K

Revenue declined 76.6% — significant demand weakness or market share loss warrants investigation.

Current Assets
Balance Sheet
-70.5%
$7.4M→$2.2M

Current assets declined 70.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-55.6%
$9.5M→$4.2M

Total assets contracted 55.6% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-07-24
PRIOR — 2024-07-29
ADDED
At July 23, 2025, the registrant had 1,934,280 shares of Common Stock, par value $0.001 per share, issued and outstanding.
References to "Fiscal 2026" refer to the 12-months ending April 30, 2026, references to "Fiscal 2025" refer to the 12-months ended April 30, 2025, and references to "Fiscal 2024" refer to the 12-months ended April 30, 2024.
In June 2025 we received Breakthrough Device designation from the FDA for the aortic stenosis algorithm licensed from Mount Sinai.
In July 2025, the American Society of Echocardiography released updated guidelines for evaluating Left Ventricular Diastolic Dysfunction ( LVDD ), placing increased emphasis on the echocardiographic measure for impaired cardiac relaxation (e ) and now requiring age-based threshold adjustments.
The device s embedded impaired cardiac relaxation algorithm already incorporates age-adjusted measures, previously agreed with the FDA.
+7 more — sign up free →
REMOVED
The stock price and the number of shares at October 31, 2023 takes into account a 1-for-100 reverse stock split which became effective on May 17, 2024 (the Reverse Stock Split ).
At July 26, 2024, the registrant had 855,966 shares of Common Stock, par value $0.001 per share, issued and outstanding post the Reverse Stock Split.
References to "Fiscal 2025" refer to the 12-months ending April 30, 2025, references to "Fiscal 2024" refer to the 12-months ended April 30, 2024, and references to "Fiscal 2023" refer to the 12-months ended April 30, 2023.
References to our IPO refer to the initial public offering of Heart Test Laboratories, Inc.
REVERSE STOCK SPLIT Effective May 17, 2024, the Company effected a 1-for-100 reverse stock split of its issued and outstanding shares of Common Stock (the Reverse Stock Split ).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →